APOE RNA Oligonucleotide Modulation for Neurodegenerative Symptoms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Alzheimer's Disease lack effective options to reduce the impact of APOE, which is linked to pathological hallmarks and increased risk, and there is a need for agents and methods to ameliorate symptoms like cognitive impairment and amyloid plaques.
Innovation Solution
Oligomeric agents, particularly modified oligonucleotides such as oligomeric duplexes and antisense oligonucleotides, are used to reduce APOE RNA and ApoE protein levels, targeting specific symptoms like cognitive impairment and amyloid plaques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If oligomeric agents are used to reduce APOE RNA and protein levels, then the amount of ApoE protein is reduced, but the complexity of the treatment increases
Solution Approach 1:
The patent uses oligomeric agents (antisense oligonucleotides, siRNA, aptamers) as intermediary molecules that specifically bind to APOE RNA to reduce protein production. These agents act as mediators between the therapeutic goal and the target gene, enabling selective reduction of ApoE protein without directly modifying the genome or requiring complex surgical interventions.
Solution Approach 2:
The patent replaces mechanical or surgical approaches with molecular-level chemical/biological mechanisms. Instead of physical interventions, the invention uses nucleic acid-based agents that exploit cellular transcription and translation machinery to achieve protein reduction, substituting mechanical complexity with biochemical specificity.
2Reliability
If APOE expression is reduced to treat neurodegenerative diseases, then symptoms like cognitive impairment and amyloid plaques are ameliorated, but the risk of affecting normal lipid transport and cholesterol metabolism increases
Solution Approach 1:
The patent applies local quality by using highly specific oligomeric agents that target only APOE RNA sequences, affecting only the expression of ApoE protein variants (particularly the harmful ε4 isoform) while leaving other apolipoproteins and lipid metabolism pathways intact. The specificity of nucleic acid binding ensures localized action on the target gene without broad metabolic disruption.
Solution Approach 2:
The patent changes the expression level parameter of APOE specifically, rather than affecting all proteins involved in lipid metabolism. By using sequence-specific oligomeric agents, the invention selectively modifies the concentration of ApoE protein (especially pathological isoforms) while maintaining normal levels of other lipoprotein components, thus altering only the necessary parameter for disease treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These agents effectively decrease the activity and amount of APOE RNA and protein, leading to amelioration of symptoms such as cognitive decline, memory loss, and amyloid plaque formation, providing a therapeutic approach for neurodegenerative diseases.
Implementation Method 1
oligomeric agents useful for reducing expression of APOE RNA comprise modified oligonucleotides... oligomeric duplexes and/or antisense oligonucleotides
Data Source
AI summary
Provided are oligomeric agents, pharmaceutical compositions, and methods for reducing the amount or activity of APOE RNA in a cell or subject, and in certain instances reducing the amount of ApoE protein in a cell or subject. Such oligomeric agents, pharmaceutical compositions, and methods are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include cognitive impairment, progressive memory loss, a decline in language skills, behavioral abnormality, dementia, difficulty performing daily activities, aphasia, agnosia, apraxia, loss of motor function, amyloid plaque, neurofibrillary tangle, and/or neuroinflammation.